Skip to main content

Table 1 Patient characteristics

From: Is total hip arthroplasty safely performed in lung transplant patients? Current experience from a retrospective study of the Zurich lung transplant cohort

Patient Sex Age y Joint indication Approach Immunosuppression Antibiotic prophylaxis Hospital stay d Interval y F/U y Subjective hip value % Harris Hip Score (HHS) points Perioperative complications Prosthetic complications
MJ f 47 Posttraumatic AVN Hardinge CYA, MMF, PRED CIP 7 11.0 11.1 90 86 None None
SB f 42 AVN Hardinge CYA, MMF, PRED TZP, TEC, CIP 39 12.2 3.1 100 100 Wound healing disturbance None
SS m 23 Posttraumatic AVN Hardinge CYA, MMF, PRED TEC, MER (INN) 16 9.4 2.0 100 97 None None
MH f 62 Pathologic Fx AMIS CYA, MMF, PRED TZP, TEC, CIP 11 3.1 2.6 90 100 None None
FS f 68 AVN AMIS CYA, MMF, PRED TZP, TEC 8 2.4 2.0 100 95 None None
  1. AVN Avascular necrosis, Fx Fracture, Hardinge Hardinge approach, AMIS Anterior minimal invasive surgery – modified Hueter approach, CYA Cyclosporine A, TAC Tacrolimus, MMF Mycophenolate Mofetil, PRED Prednisone, CIP Ciprofloxacin, MER Meropenem, TEC Teicoplanin, TZP Piperacillin/Tazobactam, INN Amoxicillin/Clavulanic acid, Interval Time from lung transplantation to total hip arthroplasty, F/U Follow-up time